Key Points
A genome-wide study of the association of over 5 million SNPs with methotrexate clearance in 1279 patients treated with HDMTX in multicenter COG trials 9904 and 9905. We replicated the finding that inherited variations in SLCO1B1 are the most important genetic variations influencing methotrexate clearance.